Apoptotic and proliferative characteristics of proliferation centers in lymph node sections of patients with chronic lymphocytic leukemia

References

• Caligaris-Cappio F, Ghia P. Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease?. J Clin Oncol 2008;20:4497–4503.
   Web of Science ®Google Scholar
• Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005;352:804–815.
   PubMed Web of Science ®Google Scholar
• Bueso-Ramos CE, Ferrajoli A, Medeiros LJ, et al. Aberrant morphology, proliferation, and apoptosis of B-cell chronic lymphocytic leukemia cells. Hematology 2004;9:279–86.
   PubMedGoogle Scholar
• Pangalis GA, Nathwani BN, Rappaport H. Malignant lymphoma, well differentiated lymphocytic: its relationship with chronic lymphocytic leukemia and macroglobulinemia of Waldenström. Cancer 1977;39:999–1010.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008.
   Google Scholar
• Schmid C, Isaacson PG. Proliferation centers in B-cell malignant lymphoma, lymphocytic (B-CLL): an immunophenotypic study. Histopathology 1994;24:445–451.
   PubMed Web of Science ®Google Scholar
• Soma LA, Craig FE, Swerdlow SH. The proliferation center microenvironment and prognostic markers in chronic lymphocytic leukemia/small lymphocytic lymphoma. Hum Pathol 2006;37:152–159.
   PubMed Web of Science ®Google Scholar
• Bonato M, Pittaluga S, Tierens A, et al. Lymph node histology in typical and atypical chronic lymphocytic leukemia. Am J Surg Pathol 1998;22:49–56.
   PubMed Web of Science ®Google Scholar
• Ponzoni M, Doglioni C, Caligaris-Cappio F. Chronic lymphocytic leukemia: the pathologist's view of lymph node microenvironment. Semin Diagn Pathol 2011;28:161–166.
   PubMed Web of Science ®Google Scholar
• Herreros B, Rodríguez-Pinilla SM, Pajares R, et al. Proliferation centers in chronic lymphocytic leukemia: the niche where NF-kappaB activation takes place. Leukemia 2010;24:872–876.
   PubMed Web of Science ®Google Scholar
• Tibbets MD, Zheng L, Lenardo MJ. The death effector domain protein family: regulators of cellular homeostasis. Nat Immunol 2003;4:404–409.
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Ohta H, Takemori T. Fas is required for clonal selection in germinal centers and the subsequent establishment of the memory B cell repertoire. Immunity 2001;14:181–192.
   PubMed Web of Science ®Google Scholar
• Thome M, Tschopp J. Regulation of lymphocyte proliferation and death by FLIP. Nat Rev Immunol 2001;1:50–58.
   PubMedGoogle Scholar
• Mathas S, Lietz A, Anagnostopoulos I, et al. c-FLIP mediates resistance of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis. J Exp Med 2004;199:1041–1052.
   PubMed Web of Science ®Google Scholar
• Lajmanovich A, Irisarri M, Molens JP, et al. Impairment of death-inducing signalling complex formation in CD95-resistant human primary lymphoma B cells. Br J Haematol 2004;124:746–753.
   PubMed Web of Science ®Google Scholar
• Peter ME, Krammer PH. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ 2003;10:26–35.
   PubMed Web of Science ®Google Scholar
• Suda T, Takahashi T, Golstein P, et al. Molecular cloning and expression of Fas Ligand, a novel member of the tumor necrosis factor factor family. Cell 1993;75:1169–1177.
   PubMed Web of Science ®Google Scholar
• Dicker F, Kater A, Fucuda T, et al. Fas-ligand (CD178) and TRAIL synergistically induce apoptosis of CD40 activated CLL B-cells. Blood 2005;105:3193–3198.
   PubMed Web of Science ®Google Scholar
• Irmler M, Thome M, Hahne M, et al. Inhibition of death receptors signals by cellular FLIP. Nature 1997;388:190–195.
   PubMed Web of Science ®Google Scholar
• Reed JC. Molecular biology of chronic lymphocytic leukemia. Semin Oncol 1998;25:11–18.
   PubMed Web of Science ®Google Scholar
• Schimmer AD, Munk-Pedersen I, Minden MD, et al. Bcl-2 and apoptosis in chronic lymphocytic leukemia. Curr Treat Options Oncol 2003;4:211–218.
   PubMedGoogle Scholar
• Deveraux QL, Reed JC. IAP family proteins-suppressors of apoptosis. Genes Dev 1999;13:239–252.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the InternationalWorkshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute-Working Group (NCI-WG) 1996 guidelines. Blood 2008;111:5446–5456.
   PubMed Web of Science ®Google Scholar
• van Dongen JJ, Langerak AW, Bruggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003;17:2257–2317.
   PubMed Web of Science ®Google Scholar
• Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343: 1910–1916.
   PubMed Web of Science ®Google Scholar
• Del Poeta G, Maurillo L, Venditti A, et al. Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood 2001;98: 2633–2639.
   PubMed Web of Science ®Google Scholar
• Giné E, Martinez A, Villamor N, et al. Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia (“accelerated” chronic lymphocytic leukemia) with aggressive clinical behavior. Haematologica 2010;95: 1526–1533.
   PubMed Web of Science ®Google Scholar
• Crespo M, Bosch F, Villamor N, et al. ZAP -70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukaemia. N Engl J Med 2003;348:1764–1775.
   PubMed Web of Science ®Google Scholar
• Jäckel MC. [Genetic control of programmed cell death (apoptosis). Prospects for biological tumor staging?]. HNO 1998;46:614–625.
   PubMed Web of Science ®Google Scholar
• Panayiotidis P, Ganeshaguru K, Foroni L, et al. Expression and function of the FAS antigen in B chronic lymphocytic leukemia and hairy cell leukemia. Leukemia 1995;9:1227–1232.
   PubMed Web of Science ®Google Scholar
• Wang D, Freeman GJ, Levine H, et al. Role of the CD40 and CD95 (APO-1/Fas) antigens in the apoptosis of human B-cell malignancies. Br J Haematol 1997;97:409–417.
   PubMed Web of Science ®Google Scholar
• Bosanquet AG, Bell PB, Rooney N. Effect of interleukin-2 on CD95 (Fas/APO-1) expression in fresh chronic lymphocytic leukaemia and mantle cell lymphoma cells: relationship to ex vivo chemoresponse. Anticancer Res 1999;19:5329–5334.
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Dixit VM. The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. Science 1998;281:1305–1308.
   PubMed Web of Science ®Google Scholar
• Wajant H. Targeting the FLICE inhibitory protein (FLIP) in cancer therapy. Mol Interv 2003;3:124–127.
   Google Scholar
• Korkolopoulou P, Goudopoulou A, Voutsinas G, et al. c-FLIP expression in bladder urothelial carcinomas: its role in resistance to Fas-mediated apoptosis and clinicopathologic correlations. Urology 2004;63:1198–1204.
   PubMed Web of Science ®Google Scholar
• Korkolopoulou P, Saetta AA, Levidou G, et al. c-FLIP expression in colorectal carcinomas: association with Fas/FasL expression and prognostic implications. Histopathology 2007;51:150–156.
   PubMed Web of Science ®Google Scholar
• Djerbi M, Screpanti V, Catrina AI, et al. The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. J Exp Med 1999;190:1025–1032.
   PubMed Web of Science ®Google Scholar
• Robertson LE, Plunkett W, McConnell K, et al. Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia 1996;10:456–459.
   PubMed Web of Science ®Google Scholar
• Schena M, Larsson LG, Gottardi D, et al. Growth- and differentiation-associated expression of bcl-2 in B-chronic lymphocytic leukemia cells. Blood 1992;79:2981–2989.
   PubMed Web of Science ®Google Scholar
• Li F, Brattain MG. Role of the survivin gene in pathophysiology. Am J Pathol 2006;169:1–11.
   PubMed Web of Science ®Google Scholar
• Paydas S, Tanriverdi K, Yavuz S, et al. Survivin and aven: two distinct antiapoptotic signals in acute leukemias. Ann Oncol 2003;14:1045–1050.
   PubMed Web of Science ®Google Scholar
• Granziero L, Ghia P, Circosta P, et al. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood 2001;97:2777–2783.
   PubMed Web of Science ®Google Scholar
• Munzert G, Kirchner D, Stobbe H, et al. Tumor necrosis factor receptor-associated factor 1 gene overexpression in B-cell chronic lymphocytic leukemia: analysis of NF-kappa B/Rel-regulated inhibitors of apoptosis. Blood 2002;100:3749–3756.
   PubMed Web of Science ®Google Scholar
• Cohen GM. Caspases: the executioners of apoptosis. Biochem J 1997;326:1–16.
   PubMed Web of Science ®Google Scholar
• Nicholson DW, Thornberry NA. Caspases: killer proteases. Trends Biochem Sci 1997;22:299–306.
   PubMed Web of Science ®Google Scholar
• Pangalis GA, Vassilakopoulos TP, Dimopoulou MN, et al. B-chronic lymphocytic leukemia: practical aspects. Hematol Oncol 2002;20:103–146.
   PubMed Web of Science ®Google Scholar
• Caligaris-Cappio F, Hamblin TJ. B-cell chronic lymphocytic leukaemia: a bird of different feather. J Clin Oncol 1999;17:399–408.
   PubMed Web of Science ®Google Scholar
• Rudner J, Jendrossek V, Belka C. New insights in the role of Bcl-2. Bcl-2 and the endoplasmic reticulum. Apoptosis 2002;7:441–447.
   Google Scholar
• Clem RJ, Cheng EH, Karp CL, et al. Modulation of cell death by Bcl-XL through caspase interaction. Proc Natl Acad Sci USA 1998;95:554–559.
   PubMed Web of Science ®Google Scholar
• Ryan AE, Shanahan F, O’Connell J, et al. Addressing the “Fas counterattack” controversy: blocking Fas ligand expression suppresses tumor immune evasion of colon cancer in vivo. Cancer Res 2005;65:9817–9823.
   PubMed Web of Science ®Google Scholar
• O’Connell J, Houston A, Bennett MW, et al. Immune privilege or inflammation?. Insights into the Fas ligand enigma. Nat Med 2001;7:271–274.
   Google Scholar
• Adida C, Haioun C, Gaulard P, et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 2000;96: 1921–1925.
   PubMed Web of Science ®Google Scholar
• Grabowski P, Kühnel T, Mühr-Wilkenshoff F, et al. Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma. Br J Cancer 2003;88:115–119.
   PubMed Web of Science ®Google Scholar
• Dong Y, Sui L, Watanabe Y, et al. Survivin expression in laryngeal squamous cell carcinomas and its prognostic implications. Anticancer Res 2002;22:2377–2383.
   PubMed Web of Science ®Google Scholar
• Ferreira CG, Tolis C, Span SW, et al. Drug-induced apoptosis in lung cancer cells is not mediated by the Fas/FasL (CD95/APO1) signaling pathway. Clin Cancer Res 2000;6:203–212.
   PubMed Web of Science ®Google Scholar
• Jones DT, Ganeshaguru K, Virchis AE, et al. Caspase 8 activation independent of Fas (CD95/APO-1) signaling may mediate killing of B-chronic lymphocytic leukemia cells by cytotoxic drugs or gamma radiation. Blood 2001;98:2800–2807.
   PubMed Web of Science ®Google Scholar
• Pedersen IM, Kitada S, Schimmer A, et al. The triterpenoid CDDO induces apoptosis in refractory CLL B cells. Blood 2002;100: 2965–2972.
   PubMed Web of Science ®Google Scholar